Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04602377
Title Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors ARCAGY/ GINECO GROUP
Indications

ovarian small cell carcinoma

Therapies

Pembrolizumab

Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab

Age Groups: adult | child | senior
Covered Countries FRA


No variant requirements are available.